Irisin was previously found to improve myocardial functions in the diabetic heart in association with an improvement in insulin sensitivity and the PRAK pathway [29], revealing that irisin-enhanced insulin sensitivity modulates cardiac performance in metabolic disorders. Here, MAPKAPK5 is linked to metabolic disease.